Industry Strength Score
68/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ADIAL PHARMACEUTICALS INC (ADIL) Stock Price & Overview
NASDAQ:ADIL • US00688A3041
Current stock price
1.55 USD
+0.01 (+0.65%)
Last:
The current stock price of ADIL is 1.55 USD. Today ADIL is up by 0.65%. In the past month the price decreased by -8.28%. In the past year, price increased by 131.34%.
ADIL Key Statistics
52-Week Range0.1323 - 3.673
Current ADIL stock price positioned within its 52-week range.
1-Month Range1.51 - 1.89
Current ADIL stock price positioned within its 1-month range.
- Market Cap
- 2.217M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -18.07
- Dividend Yield
- N/A
ADIL Stock Performance
Today
+0.65%
1 Week
-1.90%
1 Month
-8.28%
3 Months
+627.70%
Longer-term
6 Months +343.36%
1 Year +131.34%
2 Years +6.90%
3 Years +489.35%
5 Years -37.25%
10 Years N/A
ADIL Stock Chart
ADIL Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ADIL. When comparing the yearly performance of all stocks, ADIL is one of the better performing stocks in the market, outperforming 99.33% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ADIL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADIL. While ADIL seems to be doing ok healthwise, there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ADIL Earnings
Next Earnings DateMay 12, 2026
Last Earnings DateMar 5, 2026
PeriodQ4 / 2025
EPS Reported-$3.07
Revenue Reported
EPS Surprise -40.21%
Revenue Surprise %
ADIL Forecast & Estimates
9 analysts have analysed ADIL and the average price target is 25.5 USD. This implies a price increase of 1545.16% is expected in the next year compared to the current price of 1.55.
Analysts
Analysts82.22
Price Target25.5 (1545.16%)
EPS Next Y62.78%
Revenue Next YearN/A
ADIL Financial Highlights
Over the last trailing twelve months ADIL reported a non-GAAP Earnings per Share(EPS) of -18.07. The EPS increased by 62.74% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-7.98M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -119.54% | ||
| ROE | -151.19% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%64.91%
Sales Q2Q%N/A
EPS 1Y (TTM)62.74%
Revenue 1Y (TTM)N/A
ADIL Ownership
Ownership
Inst Owners9.91%
Shares1.43M
Float1.30M
Ins Owners0.32%
Short Float %3.77%
Short Ratio0.41
ADIL Industry Overview
ADIL operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
47%
Outperformed 47% of sub-industries
3 Month Rank
55%
Outperformed 55% of sub-industries
6 Month Rank
42%
Outperformed 42% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 5.2%
- New Lows
- 3%
- Average ROE
- 96.3%
- Average Profit Margin
- 29.8%
- Average Operating Margin
- 41.4%
- Average P/E
- 25.7
- Average Fwd P/E
- 17.8
- Average Debt/Equity
- 1.3
ADIL Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.63 | 910.173B | ||
| JNJ | JOHNSON & JOHNSON | 17.91 | 547.212B | ||
| MRK | MERCK & CO. INC. | 11.43 | 277.022B | ||
| PFE | PFIZER INC | 8.81 | 149.775B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 118.87B | ||
| ZTS | ZOETIS INC | 16.14 | 48.007B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.541B | ||
| VTRS | VIATRIS INC | 6.03 | 17.513B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.39 | 11.241B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.564B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.809B | ||
| CORT | CORCEPT THERAPEUTICS INC | 35.54 | 5.47B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ADIL
Company Profile
Adial Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Charlottesville, Virginia and currently employs 5 full-time employees. The company went IPO on 2018-07-27. Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Company Info
IPO: 2018-07-27
ADIAL PHARMACEUTICALS INC
1180 Seminole Trail, Suite 495
Charlottesville VIRGINIA 22901 US
CEO: William B. Stilley
Employees: 5
Phone: 14344229800
ADIAL PHARMACEUTICALS INC / ADIL FAQ
What does ADIL do?
Adial Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Charlottesville, Virginia and currently employs 5 full-time employees. The company went IPO on 2018-07-27. Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Can you provide the latest stock price for ADIAL PHARMACEUTICALS INC?
The current stock price of ADIL is 1.55 USD. The price increased by 0.65% in the last trading session.
What is the dividend status of ADIAL PHARMACEUTICALS INC?
ADIL does not pay a dividend.
What is the ChartMill rating of ADIAL PHARMACEUTICALS INC stock?
ADIL has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is ADIAL PHARMACEUTICALS INC (ADIL) stock traded?
ADIL stock is listed on the Nasdaq exchange.
What do analysts say about ADIAL PHARMACEUTICALS INC (ADIL) stock?
9 analysts have analysed ADIL and the average price target is 25.5 USD. This implies a price increase of 1545.16% is expected in the next year compared to the current price of 1.55.
What is the Price/Earnings (PE) ratio of ADIAL PHARMACEUTICALS INC (ADIL)?
ADIAL PHARMACEUTICALS INC (ADIL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.07).